PROVECTUS PHARMACEUTICALS INC

Form SC 13G/A May 31, 2006

> SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

> > SCHEDULE 13G/A

Under the Securities Exchange Act of 1934

(Amendment No. 1)*

Provectus, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

74373F100

(CUSIP Number)

May 24, 2006

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- [_] Rule 13d-1(b)
- [x] Rule 13d-1(c)
- [_] Rule 13d-1(d)

(1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No.	74373F100	13G/A	Page 2 of 5 Pages
	REPORTING PERSONS IDENTIFICATION NO. OF ABOVE	PERSONS (ENTITIES ONLY)	
Donald Ada	ams		

Edga	ar Filir	ng: PROVECT	US PHARMACE	UTICALS INC - Form SC	13G/A
2. CHECK THE	APPRO	PRIATE BOX II	F A MEMBER OF A	GROUP*	(a) [_
					(b) [_
3. SEC USE ON	LΥ				
4. CITIZENSHI	P OR	PLACE OF ORG	ANIZATION		
US					
NUMBER OF	5.	SOLE VOTING	G POWER		
SHARES		6,656,250(2	L)		
BENEFICIALLY 6. SHARE		SHARED VOT	ING POWER		
OWNED BY		0			
EACH	7.	SOLE DISPO	SITIVE POWER		
REPORTING		6,656,250(L)		
PERSON	8.	SHARED DIS	POSITIVE POWER		
WITH		0			
1,116,667 sha note into 518	res o ,657	f common and shares of con	533,333 shares nmon stock.	shares; warrants to purc of common stock; and a (9) EXCLUDES CERTAIN SHA	convertib
					[-]
11. PERCENT O	F CLA	SS REPRESENTI	ED BY AMOUNT IN	ROW (9)	
12. TYPE OF R	EPORT	ING PERSON (See Instructions	5)	
± 1 N					
CUSIP No. 743	73F10	0	13G/A	Page 3 of 5	Pages
Item 1(a). No	 ame o	f Issuer:			
Provectus, In	c.				
Item 1(b). A	ddres	s of Issuer's	s Principal Exec	cutive Offices:	
7327 Oak Ridge Knoxville, Te:					

2

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

Item 2(a).	Item 2(a). Name of Person Filing:					
Donald Adam	15					
Item 2(b).	tem 2(b). Address of Principal Business Office, or if None, Residence:					
370 Crestmo	nt Drive, San Luis Obispo, CA 93401					
Item 2(c).	Citizenship:					
US						
Item 2(d).	Title of Class of Securities:					
Common Stoc	k					
Item 2(e).	CUSIP Number:					
74373F100						
 Item 3.	If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:					
(a)	[_] Broker or dealer registered under Section 15 of the Exchange Act.					
(b)	[_] Bank as defined in Section 3(a)(6) of the Exchange Act.					
(c)	<pre>[_] Insurance company as defined in Section 3(a)(19) of the Exchange Act.</pre>					
(d)	<pre>[_] Investment company registered under Section 8 of the Investment Company Act.</pre>					
(e)	<pre>[_] An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);</pre>					
(f)	<pre>[_] An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);</pre>					
(g)	<pre>[_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);</pre>					
(h)	<pre>[_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;</pre>					
(i)	[_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;					
(j)	[_] Group, in accordance with Rule 13d-1(b)(1)(ii)(J).					
CUSIP No. 7	4373F100 13G/A Page 4 of 5 Pages					

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

(a) Amount beneficially owned: See Row 9 of cover page

(b) Percent of class: See Row 11 of cover page

(c) Number of shares as to which such person has:

(i) Sole power to vote or to direct the vote See Row 5 of cover page,

(ii) Shared power to vote or to direct the vote See Row 6 of cover page,

(iii) Sole power to dispose or to direct the disposition of See Row 7 of cover page, $% \left({\left[{{{\rm{T}}_{\rm{T}}} \right]_{\rm{T}}} \right)$

(iv) Shared power to dispose or to direct the disposition of See Row 8 of cover page $% \left({\left[{{{\rm{cov}}} \right]_{\rm{cov}}} \right)$

Item 5. Ownership of Five Percent or Less of a Class.

NOT APPLICABLE

Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

NOT APPLICABLE

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

NOT APPLICABLE

Item 8. Identification and Classification of Members of the Group.

NOT APPLICABLE

Item 9. Notice of Dissolution of Group.

NOT APPLICABLE

Item 10. Certifications.

(a) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(b):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are

Edgar Filing: PROVECTUS PHARMACEUTICALS INC - Form SC 13G/A

not held in connection with or as a participant in any transaction having such purpose or effect."

NOT APPLICABLE

(b) The following certification shall be included if the statement is filed pursuant to Rule 13d-1(c):

"By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect."

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, ${\tt I}$ certify that the information set forth in this statement is true, complete and correct.

May 31, 2006 (Date)

DONALD ADAMS BY: /s/ DONALD ADAMS (Signature)

Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7(b) for other parties for whom copies are to be sent.

Attention. Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).